Skip to main content
. 2020 Mar 17;94(7):e02149-19. doi: 10.1128/JVI.02149-19

TABLE 4.

Summary of CC50, EC50, and SI values of the compounds against seasonal H1N1 and H3N2 IAVs and IBV during posttreatment in MDCK cells

Virusa Compound Activity statistics of compound against virusb
CC50 (MTT) (μM) CC50 (XTT) EC50 SI (MTT) SI (XTT)
pH1N1 AmA >50.00 <2.54 nM 5.93 nM >8,431.70 <0.43
pH1N1 BRQ >50.00 >50.00 μM 0.78 μM >64.10 >64.10
pH1N1 6-Azauridine 42.66 >50.00 μM 0.52 μM 82.04 >96.15
pH1N1 Azaribine 19.66 >50.00 μM 0.60 μM 32.77 >83.33
pH1N1 PF 33.35 >50.00 μM 0.14 μM 238.21 >357.14
pH1N1 AVN-944 29.61 >50.00 μM 0.15 μM 197.4 >333.33
pH1N1 MMF >50.00 >50.00 μM 1.23 μM >40.65 >40.65
pH1N1 MPA >50.00 >50.00 μM 2.04 μM >24.51 >24.51
pH1N1 Ribavirin >50.00 >50.00 μM 8.06 μM >6.20 >6.20
H3N2 AmA >50.00 <2.54 nM 1.08 nM >46,296.30 <2.35
H3N2 BRQ >50.00 >50.00 μM 0.62 μM >80.65 >80.65
H3N2 6-Azauridine 42.66 >50.00 μM 0.41 μM 104.05 >121.95
H3N2 Azaribine 19.66 >50.00 μM 0.77 μM 25.53 >64.94
H3N2 PF 33.35 >50.00 μM 0.28 μM 119.11 >178.57
H3N2 AVN-944 29.61 >50.00 μM 0.99 μM 29.91 >50.51
H3N2 MMF >50.00 >50.00 μM 0.36 μM 138.89 138.89
H3N2 MPA >50.00 >50.00 μM 0.83 μM 60.24 60.24
H3N2 Ribavirin >50.00 >50.00 μM 4.89 μM >10.22 >10.22
IBV AmA >50.00 <2.54 nM 5.81 nM >8,605.85 <0.44
IBV BRQ >50.00 >50.00 μM 0.25 μM >200.00 >200.00
IBV 6-Azauridine 42.66 >50.00 μM 0.71 μM 60.08 >70.42
IBV Azaribine 19.66 >50.00 μM 0.80 μM 24.57 >62.50
IBV PF 33.35 >50.00 μM 63.51 nM 525.11 >787.28
IBV AVN-944 29.61 >50.00 μM 0.11 μM 269.18 >454.54
IBV MMF >50.00 >50.00 μM 0.10 μM >500.00 >500.00
IBV MPA >50.00 >50.00 μM 0.79 μM >63.29 >63.29
IBV Ribavirin >50.00 >50.00 μM 0.11 μM >454.55 >454.55
a

pH1N1, A/California/04/09 H1N1; H3N2, A/Wyoming/03/03 H3N2; IBV, B/Brisbane/60/08.

b

CC50, median 50% cytotoxicity concentration; EC50, median 50% effective concentration; SI, selective index (CC50/EC50).